uploads///Chart

How Eli Lilly’s Business Segments Performed in Q2 2018

By

Aug. 31 2018, Updated 6:05 p.m. ET

Business segments

Eli Lilly and Company (LLY) reports its business revenue under two segments: the Human Pharmaceutical segment and Elanco, the Animal Health segment.

The chart above compares Eli Lilly’s quarterly revenues in each segment since the first quarter of 2017.

Article continues below advertisement

Human Pharmaceutical segment

The Human Pharmaceutical segment contributed over 87.5% of Eli Lilly’s total revenue in the second quarter, reporting an 8% rise in YoY revenue to $5.6 billion compared to the second quarter of 2017. The segment includes products from various therapeutic areas, including neuroscience, endocrinology, oncology, and cardiology.

The segment’s US sales reported an 11% rise in the second quarter driven by 9% growth in volumes and a 1% favorable impact of prices.

The segment’s European sales reported a 14% rise in the quarter driven by 8% growth in volumes and a 9% favorable impact of foreign exchange, partially offset by a 3% negative impact of prices.

The segment’s Japanese sales reported a 6% rise in the quarter driven by ~12% growth in volumes and a 3% favorable impact of foreign exchange, partially offset by an 8% negative impact of prices.

The segment’s sales in the rest of the world reported a 10% rise in the quarter driven by ~4% growth in volumes, a 4% favorable impact of prices, and a 2% favorable impact of foreign exchange.

Elanco, the Animal Health segment

Eli Lilly operates its Animal Health segment through Elanco. Elanco contributed ~12.5% to the company’s total revenue in the second quarter at $792.1 million. Its revenue rose 1% during the quarter driven by a 1% favorable impact of foreign exchange and a 2% favorable impact of prices and partially offset by a 2% decrease in volumes.

The iShares US Pharmaceuticals ETF (IHE) holds 6.8% of its total investments in Eli Lilly, 8.0% in Merck & Co. (MRK), 9.1% in Pfizer (PFE), and 2.5% in Perrigo (PRGO).

Advertisement

More From Market Realist